| PSF | peak scatter factor; peptide supply factor; point spread function; pseudosarcomatous fasciitis |
|---|---|
| RIF | radiological interface; release-inhibiting factor; rifampin; right iliac fossa; rosette-inhibiting f... |
| SBF | serologic-blocking factor; specific blocking factor; splanchnic blood flow |
| SDF | slow death factor; stress distribution factor |
| SGF | sarcoma growth factor; skeletal growth factor |
| insulin-like growth-factor binding protein 1 | One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29) (12 Dec 1998) |
|---|---|
| insulin-like growth factor-binding protein 2 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth factor binding protein 3 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin like growth-factor-binding protein 4 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding-protein 5 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like-growth-factor-binding protein 6 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding proteins | A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9) (12 Dec 1998) |
| insulin-like growth factor I | <chemical> A well-characterised basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to insulin-like growth factor II, which is a major foetal growth factor. Chemical name: Insulin-like growth factor I (12 Dec 1998) |
| insulin-like growth factor II | <chemical> A well-characterised neutral peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be a major foetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults. Chemical name: Insulin-like growth factor II (12 Dec 1998) |
| integrin modulating factor 1 | <chemical> A lipid that alters the function of leukocyte integrins; may be an unsaturated fatty acid or an isoprenoid acid Synonym: imf 1, imf-1 (05 Dec 1998) |
| intrinsic factor | A mucoprotein normally secreted by the epithelium of the stomach and that binds vitamin B12, the intrinsic factor/B12 complex is selectively absorbed by the distal ileum, though only the vitamin is taken into the cell. (18 Nov 1997) |
| osteoclast activating factor | A lymphokine that stimulates bone resorption and inhibits bone-collagen synthesis. (05 Mar 2000) |
| T-cell growth factor | <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen. A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system. It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines. Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function. Acronym: IL-2 (12 Dec 1998) |
| T-cell growth factor-1 | <cytokine> A hormone-like substance released by stimulated T lymphocytes, causes activation and differentiation of other T lymphocytes independently of antigen. A type of interleukin, a chemical messenger, a substance that can improve the body's response to disease. It stimulates the growth of certain disease-fighting blood cells in the immune system. It is secreted by Thl CD4 cells to stimulate CD8 cytotoxic T-1yrnphocytes. Interleukin 2 also increases the proliferation and maturation of the CD4 cells themselves. During HIV infection, Interleukin-2 production gradually declines. Use of interleukin 2 therapy is under study as a way to raise CD4 cell counts and restore immune function. Acronym: IL-2 (12 Dec 1998) |
| T-cell growth factor-2 | <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells. Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages. Acronym: IL-4 (12 Dec 1998) |